IPCALAB Reports Robust Q2 2024 Results with Strong Sales Growth and Stable Profit Margins
IPCALAB, a major Indian pharmaceutical company, has announced its financial results for the second quarter of the 2024 fiscal year, ending September 2024. The results reveal substantial year-over-year growth in sales and a solid profit margin, underscoring IPCALAB’s strong performance in the Indian market. Below is a comparison of IPCALAB’s Q2 2024 results with the previous quarter (Q1 2024) and the same quarter last year (Q2 2023).
Key Highlights and Comparative Analysis
Sales Growth
- Q2 2024 vs. Q1 2024: Sales rose from ₹2093 crores in Q1 2024 to ₹2355 crores in Q2 2024, a notable 12.5% increase quarter-over-quarter.
- Q2 2024 vs. Q2 2023: Year-over-year sales increased by 15.8%, from ₹2034 crores in Q2 2023 to ₹2355 crores in Q2 2024.
Net Profit
- Net profit surged to ₹246 crores in Q2 2024, compared to ₹199 crores in Q1 2024 and ₹136 crores in Q2 2023, showcasing strong profitability and a year-over-year growth of approximately 80%.
Operating Profit Margin
- The operating profit margin remained stable at 19% in both Q2 2024 and Q1 2024, marking an improvement over the 18% margin recorded in Q2 2023.
Other Income
- Other income for Q2 2024 was ₹26 crores, an increase from ₹21 crores in Q1 2024 and a substantial improvement from the loss of ₹1 crore in Q2 2023.
Earnings Per Share (EPS)
- EPS improved to ₹9.05 in Q2 2024, up from ₹7.58 in Q1 2024 and ₹5.72 in Q2 2023, reflecting the company’s enhanced earnings per share over the year.